Group 1 - Fosen Pharmaceutical (01652.HK) experienced a significant increase in stock price, rising over 7% [1] - As of the latest update, the stock price reached 0.88 HKD, reflecting a gain of 7.32% [1] - The trading volume amounted to 1.264 million HKD [1]

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., developed "Mei Asha Tan Potassium Tablets," which have received regulatory approval for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" medications play a crucial role within the family of antihypertensive drugs, indicating strong market demand and potential for growth in this segment [1]

Core Viewpoint - Fosen Pharmaceutical (01652) shares rose over 7% following the approval of its hypertension treatment, "Mei Asha Tan Potassium Tablets," by the National Medical Products Administration of China [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., received approval for "Mei Asha Tan Potassium Tablets," which are indicated for the treatment of primary hypertension [1] - The active ingredient, Mei Asha Tan Potassium, is an angiotensin II receptor antagonist that converts rapidly to the active component Azilsartan upon oral absorption, effectively lowering blood pressure by blocking the angiotensin II hormone [1] Industry Summary - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 100 billion RMB in 2022 [1] - "Sartan" drugs play a crucial role within the family of antihypertensive medications, indicating strong market demand and potential for growth in this segment [1]

Core Insights - The company has received approval from the National Medical Products Administration of China for its product "Mebsartan Potassium Tablets" (trademark: Kuanopeng), which is indicated for the treatment of primary hypertension [1][2] - "Mebsartan Potassium" is a significant addition to the company's product pipeline in the cardiovascular system sector, providing more treatment options for adult patients with primary hypertension [2] Group 1: Product Details - "Mebsartan Potassium" is an angiotensin II receptor antagonist that converts rapidly to its active form, Azilsartan, after oral administration, effectively lowering blood pressure by blocking angiotensin II hormone [1] - The product is classified as a Category B drug by the National Medical Insurance Administration, with no restrictions on insurance indications or disease types, making it a first-line antihypertensive medication for adults [1] Group 2: Market Context - The "sartan" class of antihypertensive drugs holds over 80% market share in the overall renin-angiotensin system (RAS) market, with sales exceeding 10 billion RMB in 2022, highlighting its importance in the hypertension drug family [1] - The company’s "Mebsartan Potassium Tablets" are available in 40mg and 80mg dosages, catering to both mild to moderate and severe hypertension patients [2]

在整体肾素—血管紧张素系统(RAS)市场中，有超过80%的份额被"沙坦"类单一及各类联合疗法用药占 据，2022年销售额超100亿元人民币，"沙坦"类降压药在整个高血压药物家族中占据重要位置。 "美阿沙坦钾片"的主要成分美阿沙坦钾属于血管紧张素II受体拮抗剂，口服吸收后迅速转化为活性成分 阿齐沙坦，可通过阻断血管紧张素II荷尔蒙而起到降压的作用。 "美阿沙坦钾片"是国家医疗保障局乙类药物，且无医保适应症及病种限制，目前已成为国内外治疗成人 原发性高血压的一线降压药物。其具有降压效果显著;降压作用持久、稳定;器官保护作用更强等优势。 我公司开发的"美阿沙坦钾片"，与原研剂型一致，通过药学和临床(BE)研究达到其品质和疗效与参比制 剂一致，保障患者用药安全、有效，风险—获益比与参比制剂相当。 福森药业(01652)发布公告，本集团的全资附属公司嘉亨(珠海横琴)医药科技有限公司研发的"美阿沙坦 钾片"(商标：快诺平)，上市申请已获得中国国家药品监督管理局批准，批准用于原发性高血压的治 疗。 "美阿沙坦钾片"是本集团又一重要产品，进一步丰富了本集团在血液循环系统领域的医疗产品管线。 40mg和80mg两种规格，可分别 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 自願公告 「美阿沙坦鉀片」獲批上市 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團之全資附屬公司嘉亨（ 珠海橫琴 ）醫藥科技有限公司研發的「美 阿 沙 坦 鉀 片」（ 商 標 ： 快 諾 平 ）， 上 市 申 請 已 獲 得 中 國 國 家 藥 品 監 督 管 理 局 批 准 ， 批准用於原發性高血壓的治療。 「美阿沙坦鉀片」的主要成分美阿沙坦鉀屬於血管緊張素II受體拮抗劑，口服吸收 後迅速轉化為活性成分阿齊沙坦，可通過阻斷血管緊張素II荷爾蒙而起到降壓的 作用。 – 1 – 「美阿沙坦鉀片」是本集團又一重要產品，進一步豐富了 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: 2025年10月31日 | | --- | | 狀態: 新提交 | 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20, ...

Market Overview - The A-share market experienced an overall decline on October 31, with major indices showing slight decreases. The Shanghai Composite Index fell by 0.63%, the Shenzhen Component Index decreased by 0.62%, and the ChiNext Index dropped by 1.49% [4][5]. Sector Performance - The media and biopharmaceutical sectors saw significant gains, with the media sector rising over 3% and individual stocks hitting the daily limit up. Notable stocks included Fushi Holdings and Rongxin Culture, both reaching the 20% limit up [5][6]. - The biopharmaceutical sector also performed well, with a nearly 2% increase and several stocks, including Sanofi and Lianhuan Pharmaceutical, hitting the daily limit up [5][7]. Notable Stocks - In the media sector, key stocks included: - Fushi Holdings: Current price 5.08, up 0.85, a rise of 20.09% - Rongxin Culture: Current price 39.60, up 6.60, a rise of 20.00% - Visual China: Current price 22.17, up 2.02, a rise of 10.02% [6]. - In the biopharmaceutical sector, notable stocks included: - Sanofi: Current price 72.96, up 12.16, a rise of 20.00% - Lianhuan Pharmaceutical: Current price 21.77, up 1.98, a rise of 10.01% [7]. Declining Stocks - Several previously popular stocks, such as Yizhongtian, experienced significant declines. For instance, Xinyi Sheng fell by 6.44%, and Tianfu Communication dropped by 7.76% after a previous decline of 11.56% [9]. Hong Kong Market - The Hong Kong market also saw a general decline, with the Hang Seng Index approaching the 26,000-point mark. Notable declines were observed in stocks like SMIC and BYD [11]. - However, Fosen Pharmaceutical experienced a surge, with its stock price increasing by over 80% after announcing the approval of its drug Enzalutamide soft capsules for prostate cancer treatment [10][12].

Market Overview - The Hang Seng Index fell by 0.89%, down 232 points, closing at 26,050 points, while the Hang Seng Tech Index dropped by 1.91% [1] - The early trading volume in the Hong Kong stock market reached HKD 142.3 billion [1] Biotechnology Sector - The Hang Seng Biotechnology Index rebounded by 2.16%, with notable gains in several stocks: - InnoCare Pharma (09606) surged by 10.88% - 3SBio (01530) increased by over 10% - Innovent Biologics rose by 6.82% - Kelun-Biotech (06990) gained 5.69% [1] - Fosen Pharmaceuticals (01652) saw a significant increase, with a peak rise of nearly 74% and an early gain of 59.42% following the approval of Enzalutamide soft capsules and the potential selection of Metformin and Empagliflozin for national procurement [1] - Rongchang Biopharma (09995) rose by 6.75%, reporting a 40% year-on-year revenue growth and a significant reduction in losses for the first three quarters [1] Medical Sector - Spring Medical (01858) increased by over 21%, turning a profit of HKD 77.06 million in the third quarter as the company actively expands its international market [2] New Stocks Performance - Newly listed Dipo Technology (01384) continued to rise, gaining 18.97% and doubling its stock price within three days of listing [3] Financial Sector - China Everbright Bank (06818) fell by 5% post-earnings, with both revenue and profit declining in the third quarter, facing pressure from fair value changes [4] Other Notable Stocks - Huahao Zhongtian Pharmaceutical-B (02563) experienced a significant drop of over 37% due to a large unlock of shares after one year of listing [5] - Lion Holdings (02562) plummeted over 24% to a new low, planning to issue convertible bonds to raise approximately HKD 260 million for investments in gold and related products [6] - Air China (00753) dropped over 8%, with a more than 11% decline in net profit for the third quarter, and plans to raise up to HKD 20 billion through A-share placement [7]

Group 1: Hong Kong Stock Market Updates - China Metallurgical Group (01618) saw a decline of over 5%, reporting a revenue of 335.09 billion yuan for the first three quarters, a year-on-year decrease of 18.79%, and a net profit of 3.97 billion yuan, down 41.88% [1] - Fosen Pharmaceutical (01652) surged nearly 74% after announcing that its subsidiary received approval for the "Enzalutamide Soft Capsule" from the National Medical Products Administration of China [1] - Sanhua Intelligent Control (02050) increased over 3%, with a revenue of 24.03 billion yuan for the first three quarters, a year-on-year growth of 16.86%, and a net profit of 3.24 billion yuan, up 40.85% [1] - Rongchang Biopharmaceutical (09995) rose over 5%, reporting a revenue of approximately 1.72 billion yuan, a year-on-year increase of 42.27%, and a net loss of about 551 million yuan, narrowing by 48.6% [1] - New Special Energy (01799) fell nearly 8%, with a revenue of 11.66 billion yuan and a net loss of 526 million yuan for the first three quarters [1] Group 2: Additional Hong Kong Stock Market Updates - Chuny Medical (01858) increased over 10%, reporting a revenue of 756 million yuan, a year-on-year growth of 48.75%, and a net profit of 192 million yuan, up 213.21% [2] - Innovent Biologics (01801) rose over 4%, achieving total product revenue exceeding 3.3 billion yuan in Q3, maintaining a strong year-on-year growth of about 40% [2] - Longpan Technology (02465) increased over 6%, with a revenue of approximately 5.83 billion yuan, a year-on-year growth of 2.91%, and a net loss of about 110 million yuan, narrowing by 63.53% [2] - 3SBio (01530) saw an early morning increase of nearly 7%, following a significant deal with Pfizer worth up to $12.5 billion [2] - China CNR Corporation (01766) fell over 8%, reporting a revenue of approximately 183.87 billion yuan, a year-on-year increase of 20.49%, and a net profit of about 9.96 billion yuan, up 37.53% [2] Group 3: US Stock Market Updates - Carvana (CVNA.US) dropped over 13%, reporting a Q3 revenue growth of 54.5% to $5.65 billion, exceeding analyst expectations [3] - Alphabet (GOOGL.US) rose nearly 2%, with Q3 revenue surpassing $100 billion, driven by strong AI demand boosting cloud business [3] - Meta Platforms (META.US) fell over 11%, reporting Q3 revenue of $51.2 billion, a 26% year-on-year increase, but net profit significantly below expectations due to a one-time tax expense [4] - Bitcoin-related stocks experienced declines, with Strategy (MSTR.US) down nearly 7% and Coinbase (COIN.US) down over 5% [4] - eBay (EBAY.US) plummeted 15%, marking its largest drop in over 20 years despite exceeding sales expectations [4] Group 4: Additional US Stock Market Updates - Comcast (CMCSA.US) fell 4%, losing 104,000 broadband users in Q3, marking the tenth consecutive quarter of user decline [5] - CoreWeave (CRWV.US) dropped over 6% after shareholders rejected a proposed acquisition [5] - Roblox (RBLX.US) fell over 15%, reporting Q3 revenue of $1.4 billion, a 48% year-on-year increase, but widening net losses [5] - Moderna (MRNA.US) rose over 13%, reportedly in talks for a large-scale acquisition with a major pharmaceutical company [6] - Altria (MO.US) fell over 7%, reporting adjusted EPS of $1.45, in line with market consensus, but net revenue declined by 1.7% [6]